Table 2.
Baseline characteristics of patients with thyroid cancer (continuation)
| Characteristics | No prior RAI or evidence of distant metastatic disease (Group 1) | History of prior RAI and/or known distant metastatic disease (Group 2/Group 3) | |||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Concordant scans (n=289) | Discordant scans (n=22) | P | Concordant scans (n=19) | Discordant scans (n=12) | P | ||
| Gender, n (%) | Female | 188 (65) | 13 (59) | 0.6 | 11 (58) | 5 (42) | 0.4 |
| Race, n (%) | White | 229 (79) | 13 (59) | 0.04 | 16 (84) | 7 (59) | 0.2 |
| Black | 37 (13) | 4 (18) | 2 (11) | 4 (33) | |||
| Other | 23 (8) | 5 (23) | 1 (5) | 1 (8) | |||
| Pathology, n (%) | PTC | 241 (83) | 19 (86) | 0.6 | 11 (58) | 9 (75) | 0.4 |
| FTC | 14 (5) | 2 (9) | 3 (16) | 0 | |||
| HCC | 15 (5) | 0 | 1 (5) | 0 | |||
| Other* | 19 (7) | 1 (5) | 4 (21) | 3 (25) | |||
| Staging, n (%) | Stage I | 194 (67) | 15 (68) | 0.7 | 9 (47) | 3 (25) | 0.07 |
| Stage II | 25 (9) | 1 (5) | 0 | 0 | |||
| Stage III | 57 (20) | 4 (18) | 6 (32) | 1 (8) | |||
| Stage IVa | 13 (4) | 2 (9) | 1 (5) | 3 (25) | |||
| M1 | 0 | 0 | 3 (16) | 5 (42) | |||
| Preparation method, n (%) | Hormone withdrawal | 187 (65) | 11 (50) | 0.2 | 18 (95) | 12 (100) | 0.4 |
| rh-TSH | 102 (35) | 11 (50) | 1 (5) | 0 | |||
PTC=papillary thyroid cancer, FTC=follicular thyroid cancer, HCC=Hurthle cell carcinoma, Other PTC variants, rh-TSH=recombinant human TSH, RAI=radioactive therapy with 131I.